IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

ABSTRACTImmune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms acting on innate immune cells could significantly improve the incidence of c...

Full description

Bibliographic Details
Main Authors: John P. Dowling, Pavel A. Nikitin, Fang Shen, Halley Shukla, James P. Finn, Nirja Patel, Cezary Swider, Jamie L. Bingaman-Steele, Chris Nicolescu, Eden L Sikorski, Evan J. Greenawalt, Michael J. Morin, Matthew K. Robinson, Karen Lundgren, Benjamin C. Harman
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
cancer
IL-1 family
IL-38
inflammation
innate immunity
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2212673

Similar Items

Similar Items